Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Dey, Nandini ^a,f   Young, Brandon ^a,e   Abramovitz, Mark ^b,g   Bouzyk, Mark ^c,h   Barwick, Benjamin ^d   De, Pradip ^a,f   Leyland Jones, Brian ^a,f  

^a SANFORD RESEARCH   (United States)

^b VM Institute of Research   (Canada)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF SOUTH DAKOTA   (United States)

^g UNIVERSITY OF MONTREAL   (Canada)

^h AKESOgen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MATRILYSIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; SURVIVIN; WNT PROTEIN; WNT11 PROTEIN; WNT5B PROTEIN; WNT6 PROTEIN; WNT7B PROTEIN; WNT9B PROTEIN;

ARTICLE; AXIN GENE; CANCER CELL; CELL SUBPOPULATION; CONTROLLED STUDY; DOWN REGULATION; DVL1 GENE; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE C JUN; PLAUR GENE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TCF4 GENE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VEGFA GENE;

BETA CATENIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 7; NEOPLASM, RESIDUAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION; WNT PROTEINS;

EID: 84885451161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077425     Document Type: Article

References (75)

1. Bilici A, Arslan C, Altundag K, (2012) Promising therapeutic options in triple-negative breast cancer. Journal of BUON 17: 209-222.
2. Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, et al. (2013) Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast (Edinburgh, Scotland).
3. Pires MM, Hopkins BD, Saal LH, Parsons RE, (2013) Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biology and Therapy 14: 246-253.
4. Carey LA, (2011) Directed therapy of subtypes of triple-negative breast cancer. Oncologist 16 (Suppl 1):: 71-78.
5. Moulder SL, (2010) Does the PI3K pathway play a role in basal breast cancer? Clinical Breast Cancer 10: S66-S71.
6. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research 15: 4649-4664.
7. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
8. Prat A, Perou CM, (2010) WITHDRAWN: deconstructing the molecular portraits of breast cancer. Mol Oncol.
9. Martins FC, De S, Almendro V, Gonen M, Park SY, et al. (2012) Evolutionary pathways in BRCA1-associated breast tumors. Cancerologie Discovery 2: 503-511.
10. Nusse R, Varmus HE, (1992) Wnt genes. Cell 69: 1073-1087.
11. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE, (2007) Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Research 9: R63.
12. Turashvili G, Bouchal J, Burkadze G, Kolar Z, (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73: 213-223.
13. Jonsson M, Borg A, Nilbert M, Andersson T, (2000) Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. European Journal of Cancer 36: 242-248.
14. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA, (2009) Dysregulation of hedgehog, Wnt and notch signalling pathways in breast cancer. Histology and Histopathology 24: 385-398.
15. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, et al. (2011) Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Modern Pathology 24: 209-231.
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
17. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology 18: 1133-1144.
18. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27: 1160-1167.
19. Dey N, Barwick B, Moreno C, Ordanic-Kodani M, Chen Z, et al. (2013) Wnt signaling in triple negative breast cancer is associated with Poor prognosis and metastasis. BMC cancer MS under revision.
20. Barwick BG, Abramovitz Mark, Tang Weining, Kodani Maja, Oprea Gabriela M, et al.Differential Wnt Pathway Activation in Triple Negative Breast Cancers Comparative to HER2 and Hormone Positive Breast Cancers Identified from Formalin-Fixed, Paraffin-Embedded Tissues; 2008 San Antonio, Texas.
21. Wend P, Runke S, Wend K, Anchondo B, Yesayan M, et al. (2013) WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Molecular Medicine 5: 264-279.
22. Abramovitz M, Barwick BG, Willis S, Young B, Catzavelos C, et al. (2011) Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. British Journal of Cancer 105: 1574-1581.
23. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, et al. (2008) Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. BioTechniques 44: 417-423.
24. Abramovitz M, Catzavelos C, Li Z, Kodani M, Barwick B, et al. Identification of Matrix Metalloproteinase 7 (MMP7) as a Selective Biomarker of the Triple Negative Breast Cancer Subtype;(2009); Colorado, Denver.
25. Abramovitz M, Leyland-Jones B, (2007) Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment. Cancer Genomics and Proteomics 4: 135-145.
26. Dey N, De PK, Wang M, Zhang H, Dobrota EA, et al. (2007) CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Molecular and Cellular Biology 27: 4179-4197.
27. Dey N, Howell BW, De PK, Durden DL, (2005) CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Experimental Cell Research 307: 1-14.
28. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-620.
29. Bao R, Christova T, Song S, Angers S, Yan X, et al. (2012) Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLOS ONE 7: e48670.
30. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, et al. (2011) Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prevention Researcher 4: 1275-1284.
31. Dey N, Kerstann K, De P, Barwick B, Marcus A, et al. (2009) Cell Line Based Model to Study Wnt-Beta Catenin Pathway in the Control of Tumor Phenotypes in Triple Negative Subset of Breast Cancer; AACR, Denver, CO.
32. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, et al. (2013) An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemotherapy and Pharmacology 71: 867-881.
33. Pradip D, Bouzyk M, Dey N, Leyland-Jones B, (2013) Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. American Journal Cancerologie Resources 3: 173-195.
34. Preet R, Mohapatra P, Das D, Satapathy SR, Choudhuri T, et al. (2013) Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis 34: 277-286.
35. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proceedings of the National Academy of Sciences of the United States of America 97: 4262-4266.
36. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
37. Su JD, Mayo LD, Donner DB, Durden DL, (2003) PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Research 63: 3585-3592.
38. Conlin AK, Seidman AD, (2008) Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clinical Breast Cancer 8: 215-223.
39. Elias AD, (2010) Triple-negative breast cancer: a short review. American Journal of Clinical Oncology 33: 637-645.
40. Corkery B, Crown J, Clynes M, O'Donovan N, (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology 20: 862-867.
41. Shiu KK, Tan DS, Reis-Filho JS, (2008) Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opinion on Therapeutic Targets 12: 1123-1137.
42. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. Journal of Clinical Oncology 30: 1879-1887.
43. Perou CM, (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16 (Suppl 1):: 61-70.
44. Criscitiello C, Azim HA Jr., Schouten PC, Linn SC, Sotiriou C, (2012) Understanding the biology of triple-negative breast cancer. Annals of Oncology 23 (Suppl 6):: vi13-vi18.
45. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121: 2750-2767.
46. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, et al. (2008) Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiology, Biomarkers and Prevention 17: 2101-2108.
47. Yang L, Wu X, Wang Y, Zhang K, Wu J, et al. (2011) FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene.
48. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. American Journal of Pathology 176: 2911-2920.
49. Angers S, Moon RT, (2009) Proximal events in Wnt signal transduction. Nature Reviews. Molecular Cell Biology 10: 468-477.
50. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, et al. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiology, Biomarkers and Prevention 19: 301-309.
51. Beeghly-Fadiel A, Long JR, Gao YT, Li C, Qu S, et al. (2008) Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Research 68: 6453-6459.
52. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM, (1998) The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Research 58: 5500-5506.
53. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, et al. (2005) Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clinical Cancer Research 11: 6012-6019.
54. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, et al. (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. Journal of Clinical Oncology 27: 4515-4521.
55. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA, (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Research and Treatment 121: 281-292.
56. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation.
57. Lacroix M, Leclercq G, (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Research and Treatment 83: 249-289.
58. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLOS ONE 4: e6146.
59. Benhaj K, Akcali KC, Ozturk M, (2006) Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncology Reports 15: 701-707.
60. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, et al. (2008) Functional interaction between Wnt3 and frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. Journal of Hepatology 48: 780-791.
61. Wu Y, Ginther C, Kim J, Mosher N, Chung S, et al. (2012) Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Molecular Cancer Research 10: 1597-1606.
62. Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I, (2005) Upregulation of TCF4 expression as a transcriptional target of beta-catenin/p300 complexes during trans-differentiation of endometrial carcinoma cells. Laboratory Investigation 85: 768-779.
63. Sievers S, Fritzsch C, Grzegorczyk M, Kuhnen C, Muller O, (2006) Absolute beta-catenin concentrations in Wnt pathway-stimulated and non-stimulated cells. Biomarkers 11: 270-278.
64. Stambolic V, (2002) PTEN: a new twist on beta-catenin? Trends in Pharmacological Sciences 23: 104-106.
65. Wen-hua B, Zhong-xin L, Lei L, (2011) Expression of MMP-7 and PTEN in non-small cell lung cancer and its significance. Heilongjiang medicine and pharmacy.
66. Zheng HC, Sun JM, Li XH, Yang XF, Zhang YC, et al. (2003) Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathology International 53: 659-666.
67. Bi Z, Dong LD, Gu XM, (2012) Clinical significance of MMP-7 and PTEN expression in colorectal cancer. Hepatogastroenterology 60.
68. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, et al. (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891.
69. Zeng ZS, Shu WP, Cohen AM, Guillem JG, (2002) Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clinical Cancer Research 8: 144-148.
70. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, et al. (2009) Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. International Journal of Colorectal Disease 24: 875-884.
71. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, et al. (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Medical Genomics 5: 44.
72. Yamashita K, Azumano I, Mai M, Okada Y, (1998) Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. International Journal of Cancer 79: 187-194.
73. Matono H, Oda Y, Nakamori M, Tamiya S, Yamamoto H, et al. (2008) Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors. Human Pathology 39: 1802-1808.
74. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T, (1999) Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. American Journal of Pathology 155: 1033-1038.
75. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y, (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Experimental Biology and Medicine (Maywood) 231: 20-27.